BioLineRx Presents Groundbreaking Data on Pancreatic Cancer Treatment at ASCO 2025 Annual Meeting

BioLineRx's New Pilot Phase Data on Pancreatic Cancer



BioLineRx Ltd., a biopharmaceutical company focused on oncology and rare diseases, recently announced a significant update from its Phase 2 clinical trial involving the drug Motixafortide in the treatment of first-line pancreatic ductal adenocarcinoma (PDAC). This ground-breaking data was presented at the 2025 ASCO Annual Meeting held in Chicago from May 30 to June 3.

The CheMo4METPANC trial, which is an investigator-initiated clinical study, evaluates the efficacy of Motixafortide—a CXCR4 inhibitor—when combined with the PD-1 inhibitor cemiplimab and standard chemotherapies gemcitabine and nab-paclitaxel. This combination is being contrasted with the current standard treatment regimen of gemcitabine and nab-paclitaxel alone.

New findings from the pilot phase of this trial are particularly promising. The updated results indicate that four out of eleven patients (approximately 36%) have remained progression-free for over one year, marking a noteworthy achievement given the historically poor prognosis associated with pancreatic cancer. Notably, two of these patients underwent definitive treatment for their metastatic disease, showcasing remarkable outcomes; one demonstrated complete resolution of all liver lesions while the other exhibited a sustained partial response and underwent successful surgery with a pathological complete response.

An analysis conducted on pre-and on-treatment biopsies, alongside evaluations of peripheral blood mononuclear cells (PBMCs), showed an increase in CD8+ T-cell tumor infiltration across all treated patients. Those patients who achieved a partial response were also noted to have higher pre-treatment levels of CXCL12-producing cancer-associated fibroblasts, a potential indicator of their positive response to treatment.

Philip Serlin, CEO of BioLineRx, emphasized the significance of these results, stating, "The continuing positive data from the pilot phase of the CheMo4METPANC trial are extremely encouraging, especially considering the aggressive nature of pancreatic cancer. This data may indicate that our combination therapy can surmount the immunosuppressive barriers typically associated with the tumor microenvironment, leading to improved patient outcomes."

The trial, which initially aimed to enroll 30 patients, has been amended to a randomized study that will now include 108 participants, reflecting the encouraging initial results. The study is designed as a multi-center trial and focuses on evaluating the primary endpoint of progression-free survival, along with several secondary objectives including safety, overall response rate, and overall survival.

Historically, pancreatic cancer is known for its low rates of early diagnosis and dismal prognoses. It is anticipated that in the United States, around 66,000 adults will be diagnosed with this disease in 2024 alone. Early-stage diagnosis is rare, with only 12% of patients being diagnosed at a stage where surgical intervention is feasible.

Motixafortide serves as a groundbreaking therapeutic strategy by inhibiting CXCR4, a receptor known to be over-expressed in various cancers, including PDAC. By obstructing this receptor, Motixafortide is believed to bolster the immune response against the tumor, shifting immune cell populations towards a favorable anti-tumoral profile.

As BioLineRx continues to navigate the complexities of clinical trials and regulatory frameworks, the company remains dedicated to transforming innovative research into therapies that can significantly enhance patient care and outcomes. The results from the ongoing randomized portion of this important study are highly anticipated and could pave the way for new, effective treatment strategies against pancreatic cancer.

For more details about BioLineRx and their cutting-edge work in oncology, visit BioLineRx's Official Website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.